First Trust Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

First Trust Advisors’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$532K	Sell	8,811 -322	-4%	-$17.9K	﹤0.01%	2396
2026 Q1	$531K	Buy	9,133 +2,772	+44%	+$128K	﹤0.01%	2336
2025 Q4	$285K	Buy	+6,361	New	+$267K	﹤0.01%	2474

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

First Trust Advisors's XENE Position: Q2 2026 in Review

First Trust Advisors reduced its Xenon Pharmaceuticals (XENE) stake by 3.5% in Q2 2026, selling an estimated $17.9K and leaving 8,811 shares worth $532K. The position accounts for ﹤0.01% of the portfolio, ranked #2396.

First Trust Advisors first reported a position in XENE in Q4 2025 and has held it in 3 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

First Trust Advisors held 8,811 shares of Xenon Pharmaceuticals worth $532K as of Q2 2026.
First Trust Advisors sold 322 Xenon Pharmaceuticals shares in Q2 2026, an estimated $17.9K.
Xenon Pharmaceuticals made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #2396 holding.
First Trust Advisors first reported a position in Xenon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.